Finally, for the third class, which includes basal breast cancer,hepatocellular carcinoma, melanoma, and some other cancers, no significantbiomarker potential could be detected for activation of the ERK1/2 pathway. This evidence concerns the gene MAPK3 and hepatocellular carcinoma.